TrialJournal of gynecologic oncology2025

Toripalimab combined with bevacizumab plus chemotherapy as first-line treatment for refractory recurrent or metastatic cervical cancer: a single-arm, open-label, phase II study (JS001-ISS-CO214).

Chen Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.